TCA Cancer Research Results

TCA, Krebs/Tricarboxylic Acid Cycle: Click to Expand ⟱
Source:
Type: enzymes
Tricarboxylic Acid (TCA) cycle, also known as the Citric Acid cycle or Krebs cycle, is a key metabolic pathway that plays a central role in cellular energy production.
The TCA cycle is a series of chemical reactions that occur in the mitochondria and involve the breakdown of acetyl-CoA, a molecule produced from the breakdown of carbohydrates, fats, and proteins. The TCA cycle produces:
1. NADH and FADH2
2. ATP
3. GTP
Expression of TCA cycle enzymes is often downregulated in cancer cells.

Since cancer cells often exhibit rewired metabolism, including alterations in the use of the TCA cycle, researchers are exploring potential therapeutic interventions that target metabolic enzymes or pathways.
TCA cycle is essential for normal cellular metabolism, its role in cancer is multifaceted. Cancer cells often reprogram their metabolism—including the TCA cycle—to support rapid growth, adapt to hypoxia, and manage oxidative stress. Mutations in key TCA cycle enzymes generate oncometabolites that further contribute to cancer progression by disrupting normal cellular regulation.

Rather than saying the TCA cycle is globally over- or underexpressed in cancer, it is more accurate to say that cancer cells reprogram the cycle—with selective upregulation of parts important for biosynthesis and survival and mutations or downregulation of other parts—to best support their growth and survival in a challenging microenvironment.

Oncometabolites
-Some metabolites in the Krebs cycle, when accumulated to abnormal levels due to genetic mutations or enzyme deficiencies, are termed “oncometabolites” because they can promote tumorigenesis.
-Mutations in succinate dehydrogenase (SDH) can lead to accumulation of succinate.
-Mutations in fumarate hydratase (FH) result in an accumulation of fumarate.
-Mutations in isocitrate dehydrogenase (IDH1 and IDH2) result in a neomorphic enzyme activity that converts α-ketoglutarate (α-KG) to 2-hydroxyglutarate:


Scientific Papers found: Click to Expand⟱
1578- Citrate,    Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update
- Review, Var, NA
TCA↑,
FASN↑, Cytosolic acetyl-CoA sustains fatty acid (FA) synthesis (FAS)
Glycolysis↓,
glucoNG↑, while it enhances gluconeogenesis by promoting fructose-1,6-biphosphatase (FBPase)
PFK1↓, citrate directly inhibits the main regulators of glycolysis, phosphofructokinase-1 (PFK1) and phosphofructokinase-2 (PFK2)
PFK2↓, well-known inhibitor of PFK
FBPase↑, enhances gluconeogenesis by promoting fructose-1,6-biphosphatase (FBPase)
TumCP↓, inhibits the proliferation of various cancer cells of solid tumors (human mesothelioma, gastric and ovarian cancer cells) at high concentrations (10–20 mM),
eff↑, promoting apoptosis and the sensitization of cells to cisplatin
ACLY↓, higher concentrations (10 mM or more) decreased both acetylation and ACLY expression
Dose↑, In various cell lines, a high concentration of citrate—generally above 10 mM—inhibits the proliferation of cancer cells in a dose dependent manner
Casp3↑,
Casp2↑,
Casp8↑,
Casp9↑,
Bcl-xL↓,
Mcl-1↓,
IGF-1R↓, citrate at high concentration (10 mM) also inhibits the insulin-like growth factor-1 receptor (IGF-1R)
PI3K↓, pathways
Akt↓, activates PTEN, the key phosphatase inhibiting the PI3K/Akt pathway
mTOR↓,
PTEN↑, high dose of citrate activates PTEN
ChemoSen↑, citrate increases the sensibility of cells to chemotherapy (in particular, cisplatin)
Dose?, oral gavage of citrate sodium (4 g/kg twice a day) for several weeks (4 to 7 weeks) significantly regressed tumors

933- CUR,  EP,    Effective electrochemotherapy with curcumin in MDA-MB-231-human, triple negative breast cancer cells: A global proteomics study
- in-vitro, BC, NA
Apoptosis↑,
ALDOA↓,
ENO2↓,
LDHA↓, LDH inhibitor
LDHB↓,
PFKP↓,
PGK1↓,
PGM1↓,
PGAM1↓,
OXPHOS↑, upregulation of 10 oxidative phosphorylation pathway proteins
TCA↑, upregulation of 8 tricarboxylic acid (TCA) cycle proteins

5205- Gallo,    Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells
- in-vitro, Endo, ISH
LDH↓, novel lactate dehydrogenase (LDH) inhibitor, Galloflavin, as a therapeutic agent for endometrial cancer.
TumCG↓, Galloflavin effectively inhibited cell growth in endometrial cancer cell lines and primary cultures of human endometrial cancer
LDHA↓, GF significantly reduced LDHA activity
Apoptosis↑, GF was responsible for the activation of the mitochondrial apoptosis pathway, accompanied by an increase in cleaved caspase3 and a decrease in MCL-1 and BCL-2 protein
cl‑Casp3↑,
Mcl-1↓,
Bcl-2↓,
TumCCA↑, GF induces cell cycle changes by altering different checkpoints in different endometrial cancer cells
ROS↑, GF was also shown to increase reactive oxygen species (ROS) and mitochondrial DNA damage after 24 hours
mt-DNAdam↑,
GlucoseCon↓, Inhibition of LDHA activity by GF resulted in a decreased rate of glucose uptake and ATP production
ATP↓,
PDH↑, with subsequent increased pyruvate dehydrogenase (PDH) protein expression and production of pyruvate
Pyruv↑,
Glycolysis↓, direct effect of GF on the glucose metabolism by impairing cytosolic glycolysis in the endometrial cancer cells
TCA↑, GF increased glutaminase protein expression, and enhanced Krebs cycle activity, by increasing the production of malate,
cMyc↓, GF decreased c-Myc expression in a dose-dependent manner after 24 hours of treatment.
E-cadherin↑, E–cadherin increased while Slug proteins decreased after treatment with GF (
Slug↓,

2247- MF,    Effects of Pulsed Electromagnetic Field Treatment on Skeletal Muscle Tissue Recovery in a Rat Model of Collagenase-Induced Tendinopathy: Results from a Proteome Analysis
- in-vivo, Nor, NA
*Glycolysis↓, PEMF-treated animals exhibited decreased glycolysis and increased LDHB expression, enhancing NAD signaling and ATP production
*LDHB↑,
*NAD↑,
*ATP↑,
*antiOx↑, Antioxidant protein levels increased, controlling ROS production.
*ROS↑,
*YAP/TEAD↑, upregulation of YAP and PGC1alpha and increasing slow myosin isoforms, thus speeding up physiological recovery.
*PGC-1α↑,
*TCA↑, increased in PEMF-treated injured limbs
*FAO↑,
*OXPHOS↑, Oxidative phosphorylation was increased in the muscle of injured rats that underwent PEMF treatment

5254- NCL,    The magic bullet: Niclosamide
- Review, Var, NA
Wnt↓, In particular, niclosamide inhibits multiple oncogenic pathways such as Wnt/β-catenin, Ras, Stat3, Notch, E2F-Myc, NF-κB, and mTOR and activates tumor suppressor signaling pathways such as p53, PP2A, and AMPK.
β-catenin/ZEB1↓,
RAS↓,
STAT3↓,
NOTCH↓,
E2Fs↓,
mTOR↓,
eff↑, Moreover, niclosamide potentially improves immunotherapy by modulating pathways such as PD-1/PDL-1.
PD-1↓,
PD-L1↓, primarily through PD-L1 ligand downregulation in cancer cells.
BioAv↝, The original pharmacokinetics study showed that the maximal serum concentration can reach 0.25-6.0ug/ml (0.76-18.34 µM) following administration of a single 2g dose (11).
toxicity↓, a strong safety profile and tolerability in humans.
BioAv↑, A potential solution to the aforementioned challenge is niclosamide ethanolamine (NEN), a salt form of niclosamide that also functions as a mitochondrial uncoupler with a superior safety profile and enhanced bioavailability
ETC↑, NEN activates the ETC to boost NADH oxidation, thereby leading to an increased intracellular NAD+/NADH ratio and driving the TCA cycle forward.
NADH:NAD↓,
TCA↑,
Warburg↓, leading to a reversal of the Warburg effect and the induction of cellular differentiation
Diff↑,
AMPK↑, figure 3
P53↑,
PP2A↑,
HIF-1↓,
KRAS↓,
Myc↓,
RadioS↑, leading to a reversal of the Warburg effect and the induction of cellular differentiation
ChemoSen↑, Niclosamide has shown synergistic anti-tumor effects with a broad spectrum of chemotherapy drugs.
Dose↝, In this trial, either 500mg or 1000mg niclosamide was given three times daily to patients. However, the maximal plasma concentration ranged from 35.7–82 ng/mL (0.1µM-0.25 µM), a range that failed to be consistently above the minimum effective concent
Dose↑, In contrast, the ongoing clinical trial NCT02807805 is administering 1200 mg of reformulated orally bioavailable niclosamide orally (PO) three times daily to patients, resulting in 0.21µM-0.723 plasma niclosamide concentrations exceeding the therape

119- UA,  CUR,  RES,    Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ROS⇅, ROS↑ only with CUR alone, otherwise ↓
p‑STAT3↓, all the combination treatments decreased phosphorylation of STAT3
Src↓, All the combinations of these natural compounds also decreased phosphorylation of Src
AMPK↑,
GlutMet↑, UA in combination with both CUR or RES greatly enhanced the modulation of a number of metabolic pathways, including the “Alanine, aspartate and glutamate metabolism” and the “tricarboxylic acid (TCA) cycle”
TCA↑,
glut↓, Since the combination of CUR + UA and UA + RES decreased the uptake of glutamine

630- VitC,    Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress
- in-vitro, BC, MCF-7 - in-vitro, BC, HT-29
TCA↑,
ATP↓,
NAD↓, vitamin C caused cell death through NAD depletion in MCF7 and HT29 cells
H2O2↑,
GSH/GSSG↓,


Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

GSH/GSSG↓, 1,   H2O2↑, 1,   OXPHOS↑, 1,   ROS↑, 1,   ROS⇅, 1,  

Mitochondria & Bioenergetics

ATP↓, 2,   ETC↑, 1,  

Core Metabolism/Glycolysis

ACLY↓, 1,   ALDOA↓, 1,   AMPK↑, 2,   cMyc↓, 1,   ENO2↓, 1,   FASN↑, 1,   FBPase↑, 1,   glucoNG↑, 1,   GlucoseCon↓, 1,   glut↓, 1,   GlutMet↑, 1,   Glycolysis↓, 2,   LDH↓, 1,   LDHA↓, 2,   LDHB↓, 1,   NAD↓, 1,   NADH:NAD↓, 1,   PDH↑, 1,   PFK1↓, 1,   PFK2↓, 1,   PFKP↓, 1,   PGAM1↓, 1,   PGK1↓, 1,   PGM1↓, 1,   Pyruv↑, 1,   TCA↑, 6,   Warburg↓, 1,  

Cell Death

Akt↓, 1,   Apoptosis↑, 2,   Bcl-2↓, 1,   Bcl-xL↓, 1,   Casp2↑, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 1,   Mcl-1↓, 2,   Myc↓, 1,  

DNA Damage & Repair

mt-DNAdam↑, 1,   P53↑, 1,  

Cell Cycle & Senescence

E2Fs↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State

Diff↑, 1,   IGF-1R↓, 1,   mTOR↓, 2,   NOTCH↓, 1,   PI3K↓, 1,   PTEN↑, 1,   RAS↓, 1,   Src↓, 1,   STAT3↓, 1,   p‑STAT3↓, 1,   TumCG↓, 1,   Wnt↓, 1,  

Migration

E-cadherin↑, 1,   KRAS↓, 1,   Slug↓, 1,   TumCP↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature

HIF-1↓, 1,  

Immune & Inflammatory Signaling

PD-1↓, 1,   PD-L1↓, 1,  

Protein Aggregation

PP2A↑, 1,  

Drug Metabolism & Resistance

BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 2,   Dose?, 1,   Dose↑, 2,   Dose↝, 1,   eff↑, 2,   RadioS↑, 1,  

Clinical Biomarkers

KRAS↓, 1,   LDH↓, 1,   Myc↓, 1,   PD-L1↓, 1,  

Functional Outcomes

toxicity↓, 1,  
Total Targets: 83

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 1,   OXPHOS↑, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics

ATP↑, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis

FAO↑, 1,   Glycolysis↓, 1,   LDHB↑, 1,   NAD↑, 1,   TCA↑, 1,  

Cell Death

YAP/TEAD↑, 1,  
Total Targets: 11

Scientific Paper Hit Count for: TCA, Krebs/Tricarboxylic Acid Cycle
2 Curcumin
1 Citric Acid
1 Electrical Pulses
1 Galloflavin
1 Magnetic Fields
1 Niclosamide (Niclocide)
1 Ursolic acid
1 Resveratrol
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:818  State#:%  Dir#:2
wNotes=on sortOrder:rid,rpid

 

Home Page